Evidence map›Paper›PMID 33438181›Full record

Trial reportCardiology journal2022

Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy.

Dylan S Eiger, Lurdes Y T Inoue, Qijun Li, Gust Bardy, Kerry Lee, Jeanne Poole, Daniel Mark, Zainab Samad, Daniel Friedman, Daniel Fishbein and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dylan S EigerDepartment of Medicine, Duke University, Durham, NC, USA. dylan.eiger@duke.edu.ORCID 0000-0001-9572-6282
Lurdes Y T InoueDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Qijun LiDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Gust BardyThe Seattle Institute for Cardiac Research, Seattle, WA, USA.
Kerry LeeDepartment of Medicine, Duke University, Durham, NC, USA.
Jeanne PooleDepartment of Medicine, University of Washington, Seattle, WA, USA.
Daniel MarkDepartment of Medicine, Duke University, Durham, NC, USA.
Zainab SamadDepartment of Medicine, Duke University, Durham, NC, USA.
Daniel FriedmanDepartment of Medicine, Duke University, Durham, NC, USA.
Daniel FishbeinDepartment of Medicine, University of Washington, Seattle, WA, USA.
Gillian SandersDepartment of Medicine, Duke University, Durham, NC, USA.
Sana M Al-KhatibDepartment of Medicine, Duke University, Durham, NC, USA.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

backgroundMany patients in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) had a significant improvement (> 10%) in the left ventricular ejection fraction (LVEF) during the course of the study, but the factors and outcomes associated with such improvement are uncertain.

methodsWe examined factors and rates of mortality, cause-specific mortality, and implantable cardioverter-defibrillator (ICD) shocks associated with improvement in LVEF by analyzing patients in the SCD-HeFT who were randomized to placebo or an ICD and who had an LVEF checked during follow-up.

resultsDuring a median follow-up of 3.99 years, of 837 patients who had at least two follow-up LVEF measurements, 276 (33%) patients had > 10% improvement in LVEF and 561 (67%) patients had no significant change in LVEF. Factors significantly associated with LVEF improvement included female sex, white race, history of hypertension, a QRS duration < 120 ms, and beta-blocker use. Improvement in LVEF was associated with a significant improvement in survival. There was no significant association between improvement in LVEF and cause-specific death, but there was a significant association between improvement in LVEF and reduced risk of receiving appropriate ICD shocks.

conclusionsAbout a third of patients in this analysis, who were randomized to placebo or an ICD in SCD-HeFT, had a significant improvement in LVEF during follow-up; improvement in LVEF was associated with improved survival but not with cause-specific death, and with decreased likelihood of receiving appropriate ICD shocks.

Indexed as

CardiomyopathiesDefibrillators, ImplantableHeart FailureDeath, Sudden, CardiacFemaleHumansRisk FactorsStroke VolumeVentricular Function, Leftarrhythmiadefibrillatorheart failureimplantablesudden cardiac death

Identifiers

PMID33438181
PMCPMC9788743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.